BioVie

75 articles about BioVie

• BioVie Issues Letter to Shareholders

  12/7/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued a letter to shareholders.

• BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

  12/6/2022

  BioVie Inc.  today announced encouraging data suggesting that NE3107 has an impact on improving patients’ DNA methylation profiles, potentially impacting biomakers of aging-related disease states.

• BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

  12/5/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced positive results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease (PD) and Alzheimer’s Disease (AD).

• BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 PatientsCompany is Opting to Increase Study Size to 400 due to Fast Enrollment Pace

  11/29/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target.

• BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting

  11/15/2022

  BioVie Inc., today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer’s Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD).

• BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022

  10/24/2022

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022.

• BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

  10/19/2022

  BioVie Inc. announced that the Company’s Phase 2 trial assessing NE3107’s potential pro-motoric impact in Parkinson’s disease has fully enrolled 44 patients.

• BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference

  9/29/2022

  BioVie Inc. announced the participation of its management team in a panel discussion and one-on-one investor meetings at Cantor Fitzgerald’s Neurology & Psychiatry Conference, to be held October 6-7, 2022, in San Francisco, CA.

• 

  Clinical Catch-Up: Good News for BioVie, Regeneron, Relay and More

  9/12/2022

  ​​​​​​​The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.
• 

  BioVie Biomarker Study Points to Improvements in Alzheimer's

  9/8/2022

  ​​​​​​​BioVie announced topline results from a Phase II biomarker study in Alzheimer's disease showing patient improvements in cognition and reductions in neural inflammation.

• BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease

  9/7/2022

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced topline results from an investigator-Sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer’s Disease.

• BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

  6/23/2022

  BioVie Inc.   (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome (“HRS”) has been issued by the U.S. Patent &Trademark Office.

• BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference

  4/25/2022

  BioVie Inc. announced the participation of its management team in a fireside chat and one-on-one meetings at the B. Riley Securities’ Neuro & Ophthalmology Conference, to be held virtually April 27-28, 2022.

• BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

  3/9/2022

  BioVie Inc. announced the participation of its management team in a presentation and one-on-one investor meetings at the Oppenheimer Virtual Annual Healthcare Conference, to be held March 15-17, 2022.

• BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

  1/20/2022

  BioVie Inc. today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients.

• BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

  12/28/2021

  BioVie Inc., today announced the participation of its management team in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

• BioVie Announces Partnership with the American Liver FoundationCampaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVie’s Phase 2b Study of BIV201 for Refractory Ascites

  12/9/2021

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company’s Phase 2b Study of BIV201 (continuous infusion terlipressin).

• BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

  12/1/2021

  BioVie Inc. entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

• BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update Thursday, November 11th @ 1:00pm ET

  11/4/2021

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced that it will host a key opinion leader webinar on complications of advanced liver cirrhosis and a clinical trial update on the Phase 2b BIV201 study on Thursday, November 11, 2021, at 1:00pm Eastern Time.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.